T1	Condition 0 3;17 28	HCV coinfection
T2	Condition 17 28;5 8	coinfection HIV
T3	Condition 13 16;17 28	HDV coinfection
T4	Condition 31 34	HCC
*	OR T3 T2 T1
T5	Condition 44 54	malignancy
T6	Temporal 55 69	within 3 years
*	OR T4 T5
T7	Scope 31 54	HCC or other malignancy
R1	Has_temporal Arg1:T7 Arg2:T6	
T8	Condition 72 101	Decompensated liver cirrhosis
T9	Measurement 103 112	CTP score
T10	Value 113 116	= 7
R2	Has_value Arg1:T9 Arg2:T10	
R3	AND Arg1:T8 Arg2:T9	
T11	Condition 120 126	Uremia
T12	Procedure 142 154	hemodialysis
T13	Condition 158 199	continuous ambulatory peritoneal dialysis
T14	Measurement 217 220	Ccr
T15	Value 221 232	< 50 mL/min
*	OR T13 T12
T16	Scope 142 199	hemodialysis or continuous ambulatory peritoneal dialysis
R4	Has_value Arg1:T14 Arg2:T15	
*	OR T16 T14
T17	Scope 142 232	hemodialysis or continuous ambulatory peritoneal dialysis or patients with Ccr < 50 mL/min
R5	Has_scope Arg1:T11 Arg2:T17	
T18	Pregnancy_considerations 234 265	Pregnant or breastfeeding women
T19	Pregnancy_considerations 268 477	Women of child-bearing potential (WOCBP) who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of study drug
